M
Maria Beumont
Researcher at Janssen Pharmaceutica
Publications - 44
Citations - 3692
Maria Beumont is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Ribavirin & Telaprevir. The author has an hindex of 18, co-authored 41 publications receiving 3574 citations. Previous affiliations of Maria Beumont include Tibotec.
Papers
More filters
Journal ArticleDOI
Telaprevir for retreatment of HCV infection.
Stefan Zeuzem,Pietro Andreone,Stanislas Pol,Eric Lawitz,Moisés Diago,Stuart K. Roberts,R. Focaccia,Zobair M. Younossi,Graham R. Foster,Andrzej Horban,Peter Ferenci,Frederik Nevens,Beat Müllhaupt,Paul J. Pockros,R. Terg,Daniel Shouval,Bart van Hoek,Ola Weiland,Rolf van Heeswijk,Sandra De Meyer,Don Luo,G. Boogaerts,Ramon Polo,Gaston Picchio,Maria Beumont +24 more
TL;DR: Telaprevir combined with peginterferon plus ribavirin significantly improved rates of sustained virologic response in patients with previously treated HCV infection, regardless of whether there was a lead-in phase.
Journal ArticleDOI
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz,Mark S. Sulkowski,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M. Younossi,Ana Corregidor,Edwin DeJesus,Brian L. Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K. Lim,Paul J. Pockros,John D. Scott,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Callewaert,William T. Symonds,Gaston Picchio,Karen L Lindsay,Maria Beumont,Ira M. Jacobson +21 more
TL;DR: Combined simeprevir and sofosbuvir was efficacious and well tolerated in chronic HCV genotype 1 infections and sustained virological response 12 weeks after stopping treatment was achieved.
Journal ArticleDOI
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Graham R. Foster,Christophe Hézode,Jean-Pierre Bronowicki,Giampiero Carosi,Ola Weiland,Lieselotte Verlinden,Rolf van Heeswijk,Ben van Baelen,Gaston Picchio,Maria Beumont +9 more
TL;DR: Telaprevir monotherapy for 2 weeks reduces levels of HCV RNA in patients with chronic HCV genotype 2 infections, but has limited activity in patientsWith chronic hepatitis C virus genotype 3, the incidence of adverse events was similar among groups.
Journal ArticleDOI
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
James C. Sullivan,Sandra De Meyer,Doug J. Bartels,I. Dierynck,Eileen Z. Zhang,Joan Spanks,Ann M. Tigges,Anne Ghys,Jennifer Dorrian,Nathalie Adda,Emily C. Martin,Maria Beumont,Ira M. Jacobson,Kenneth E. Sherman,Stefan Zeuzem,Gaston Picchio,Tara L. Kieffer +16 more
TL;DR: After failure to achieve SVR with TVR-based treatment, resistant variants are observed in most patients, however, presumably due to the lower fitness of those variants, they tend to be replaced with wild-type virus over time.
Journal ArticleDOI
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C
Patrick Marcellin,Xavier Forns,Tobias Goeser,Peter Ferenci,Frederik Nevens,Giampiero Carosi,Joost P.H. Drenth,Lawrence Serfaty,Koen De Backer,Rolf van Heeswijk,Donghan Luo,Gaston Picchio,Maria Beumont +12 more
TL;DR: A high proportion of patients achieved an SVR regardless of the telaprevir dosing frequency (q8 h or q12 h) or type of peginterferon alfa used (alfa-2a or alfa-2b).